May 1, 2012
By:Nancy Gillett
Future sponsor-contract provider relationships will require more integration.
 |
April 1, 2012
By:Rita E. Numerof, Michael N. Abrams
Rather than seeking a single indication for one large group, the orphan-drug approach segments the market for a drug more minutely.
|
March 1, 2012
By:Fiona Greer
Does global development have to entail multiple comparability studies?
|
February 1, 2012
By:Frances J. Richmond
New educational programs are key to the industry's future and to safe, available drugs.
|
January 1, 2012
By:Angie Drakulich
Government plans require investment, partnership, and industry collaboration.
|
December 1, 2011
By:Christopher Milne
Reauthorization of pediatric exclusivity provisions looms in 2012 and debates begin anew.
|
November 1, 2011
By:Gerry McDougall
With the rise in therapeutics comes more complex partnerships.
|
October 1, 2011
By:Peter Soelkner
Knowing in advance what you need can make a huge difference in a sponsor company's success.
|
| 
